Viking Therapeutics
VKTX
116 hedge funds and large institutions have $300M invested in Viking Therapeutics in 2018 Q2 according to their latest regulatory filings, with 68 funds opening new positions, 28 increasing their positions, 13 reducing their positions, and 17 closing their positions.
300% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 17
228% more capital invested
Capital invested by funds: $91.4M → $300M (+$209M)
115% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 13
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
76% more funds holding
Funds holding: 66 → 116 (+50)
28% more call options, than puts
Call options by funds: $9.5M | Put options by funds: $7.4M
12.76% more ownership
Funds ownership: 41.07% → 53.84% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$29.7M |
| 2 |
BlackRock
New York
|
+$17M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$13.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.69M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$4.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$8.87M |
| 2 |
SCM
Sio Capital Management
New York
|
-$6.62M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.39M |
| 4 |
Millennium Management
New York
|
-$4.38M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$3.99M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
126
Laurion Capital Management
New York
| – | -$218K | -49,986 | Closed |
|
|
AGM
127
Alpine Global Management
New York
| – | -$175K | -40,000 | Closed |
|
|
JG
128
Jefferies Group
New York
| – | -$135K | -20,300 | Closed |
|
|
BIM
129
Bogle Investment Management
Newton Lower Falls,
Massachusetts
| – | -$80K | -18,407 | Closed |
|
|
GC
130
Guggenheim Capital
Chicago,
Illinois
| – | -$52K | -11,988 | Closed |
|
131
Verition Fund Management
Greenwich,
Connecticut
| – | -$50K | -11,546 | Closed |
|
|
IIC
132
Integrated Investment Consultants
Bloomfield Hills,
Michigan
| – | -$13K | -3,000 | Closed |
|
VKTX Hedge Fund Activity: Q2 2018 in Review
116 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q2 2018, worth a combined $300M — up 228% from $91.4M a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new VKTX positions and 17 closed out — a net gain of 51 holders — while 28 added to existing stakes and 13 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $29.7M. The largest seller was RA Capital Management, exiting entirely with an estimated $8.87M sold.
- 116 institutional investors held Viking Therapeutics (VKTX) as of Q2 2018, up from 66 in Q1 2018.
- Funds reported $300M of Viking Therapeutics stock for Q2 2018, up 228% quarter-over-quarter.
- 68 funds opened new Viking Therapeutics positions in Q2 2018 and 17 closed out, a net change of +51 holders.
- The largest Viking Therapeutics buyer in Q2 2018 was Avoro Capital Advisors, an estimated $29.7M added.
- The largest Viking Therapeutics seller in Q2 2018 was RA Capital Management, an estimated $8.87M sold.
Based on aggregated 13F filings for Q2 2018.